Does Your Patient Have a High Risk HPV Strain?
New
cervical screening guidelines from both the American Cancer Society and
the American College of Obstetricians and Gynecologists recommend women
age 30 and older be offered "Pap plus HPV DNA testing" as part of routine
cervical cancer screening.1,2
HPV infections currently affect more than 20 million individuals
worldwide. It is estimated that more than 6.2 million genital HPV
infections occur each year in the U.S. alone, and more than 80 percent
of women will have acquired HPV infections by the age of 50.3
HPV
infections currently affect more than 20 million individuals worldwide.
It is estimated that more than 6.2 million genital HPV infections occur
each year in the U.S. alone, and more than 80 percent of women will
have acquired HPV infections by the age of 50.
Our High Risk HPV Panel
As
a medical provider, you know that HPV (human papillomavirus) is a group
of more than 100 types of common viruses. Some of those viruses are
known to increase the risk of cervical cancer.
Now, thanks to
genomic medicine, you have the means to quickly, easily and
cost-effectively determine whether your patients have any of the high
risk strains of HPV, giving you the information you need to prescribe
appropriate clinical procedures or further tests.
A Cost-Effective, High Risk HPV Screen
A simple HPV DNA test can determine whether your patient has one of the genotypes that create a higher risk of cancer.
The
Iverson High Risk HPV panel is a screening test that detects 14
different strains of HPV categorized as high risk and pools them into
three groups of similar strains. As a physician, you get three "positive" or "negative" results, which you can use to determine
whether further testing or clinical procedures are needed.
The test can be used as a routine screening test and also as a follow-up to an abnormal pap.
More
than 300,000 unnecessary diagnostic procedures would be prevented
annually in the U.S. if all women aged 18 to 70 followed the DNA
testing-first strategy.
Understanding the Genetics
More
than 30 types of HPV viruses are known to increase the risk of cervical
cancer. High risk (carcinogenic) types of HPV include HPV 16, HPV 18,
HPV 30, HPV 33 and HPV 45.3 All 14 variants account for approximately 99% of all cervical cancer cases.4
About 70% of all cervical cancers are caused by
HPB 16 and 18.2
The Iverson High Risk HPV Panel tests for:
- Group A (16, 31, 33, 35, 52, 58)
- Group B (18, 39, 45, 59, 68)
- Group C (51, 56, 66)
Frequently Asked Questions
Why should I order the Iverson HPV Panel for my patients?
When
diagnosed and treated early, cervical cancer has a high cure rate. The
Iverson HPV Panel will give you critical information to help you
determine whether your patient is at risk of cancer, and to prescribe
additional tests if needed.
I'm not a geneticist. How can I interpret the test results?
Our
simplified report will clearly show whether your patient carries one of
the listed types of HPV. If you need more information, we will be happy
to work with you to make certain you have everything you need.
Will the HPV panel predict with absolute certainty whether my patient will develop cancer?
Although
the Iverson High Risk HPV Panel cannot predict whether a patient will
develop cancer, it will give you a better idea of the patient's risk,
allowing you to prescribe with greater confidence.
When should a patient be tested for High Risk HPV?
The
American Cancer Society and the American College of Obstetricians and
Gynecologists recommend women age 30 and older be offered "Pap plus HPV
DNA" as part of routine cervical cancer screening.1,2 Testing also is done as a follow-up to an abnormal pap.
References
1.
Detailed Guide: Cervical Cancer. Can Cervical Cancer Be Prevented?
[Internet]. American Cancer Society. 2008 Mar 26 [cited 2008 Oct 16].
Available from: http://www.cancer.org/docroot/CRI/content/
CRI_2_4_2X_Can_cervical_cancer_be_ prevented_8.asp
2. Revised
Cervical Cancer Screening Guidelines Require Reeducation of Women and
Physicians [Internet]. American College of Obstetricians and
Gynecologists. 2004 May 4 [cited 2008 Oct 16]. Available from:
http://www.acog.org/from_home/
publications/press_releases/nr05-04-04-1.cfm
3. Ginocchio, C.C.,
Barth, D. and Zhand, F. Comparison of the Third Wave Invader HPV Assay
and the Digene HPV Hybrid Capture 2 Assay for the Detection of
High-Risk Human Papillomavirus DNA. Journal of Clinical Microbiology.
2008;46:1641-1646.
4. Walboomer, JM, et al. Human Papillomavirus is
a Necessary Cause of Invasive Cervical Cancer Worldwide [Internet].
1999 Sep [cited 2008 Oct 20]. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/10451482
5. Stout NK, et al. Trade-offs in Cervical Cancer Prevention: Balancing Benefits and Risks. Arch Intern Med. 2008;168:1881-1889. |
